Effect of crossmatching on outcome in organ transplantation.
The complement-dependent cytotoxicity (CDC) crossmatch and the flow cytometry crossmatch (FCXM) are both used prospectively in renal transplantation, and their use is under evaluation in other types of major organ transplantation. The FCXM is the more sensitive method and better predicts outcome in second and subsequent renal allografts. Improved survival has unmasked the detrimental effect of a positive crossmatch on outcome in liver transplantation. Because of the urgent need of liver transplant candidates, it is unrealistic to defer transplantation until a crossmatch-negative donor is found; however, additional therapeutic measures may be taken to improve outcome for crossmatch-positive liver recipients. Some reports suggest that prospective crossmatching may improve outcome for sensitized heart recipients, and, additionally, recent studies have demonstrated that HLA compatibility between donor and recipient is an independent variable affecting survival after heart transplantation, prompting a reassessment of the current practice of transplanting hearts without consideration of the HLA match.
Wang-Rodriguez
J
J
Department of Pathology 0612, University of California, San Diego, La Jolla 92093, USA.
Rearden
A
A
D003165:Complement System Proteins / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D005434:Flow Cytometry; D006084:Graft Rejection; D006680:HLA Antigens; D016027:Heart Transplantation / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation / Q000276:immunology; D016031:Liver Transplantation / Q000276:immunology; D011379:Prognosis; D014181:Transplantation Immunology
D006680:HLA Antigens; D003165:Complement System Proteins